← All trials
NCT03981796
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2019
- Primary completion
- Nov 26, 2021
- Completion date
- Jul 15, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 470
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- TesaroLead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- Gynecologic Oncology GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.